ClinicalTrials.gg
CompletedNCT04709302ENDOCOVIDUpdated Oct 8, 2026

Effects of COVID-19 on Endothelium in HIV-Positive Patients in Sub-Saharan Africa

An observational study in Covid19, Hiv and ART, sponsored by Medical University of Graz. Completed at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Medical University of Graz · Observational

How we know

Updated Oct 8, 2026Now CompletedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
342
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 15 studies in COVID-19 with a site in Nigeria — none open to participants now, none under way, none of them phase 3. COVID-19 · Nigeria.

Started
2021
with 2 others
Observational
4 of 15
none open now
Registered
10th of 15
by date
Lead sponsor
1 of 15
Medical University of Graz

Among the 15 studies in COVID-19 with a site in Nigeria, this one is one of 3 that started in 2021, is one of 4 observational ones, and was the 10th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

None of the 15 studies in COVID-19 with a site in Nigeria is open now. The open studies under COVID-19, anywhere →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies in COVID-19 with a site in Nigeria as a file.
02

Study summary

Background: Coronavirus disease 2019 (COVID-19) has affected almost every country in the world, especially in terms of health system capacity and economic burden. People from sub-Saharan Africa (SSA) often face interaction between human immunodeficiency virus (HIV) infection and non-communicable diseases such as cardiovascular disease. Role of HIV infection and anti-retroviral treatment (ART) in altered cardiovascular risk is questionable and there is still need to further carry out research in this field. However, thus far it is unclear, what impact the COVID-19 co-infection in people living with HIV (PLHIV), with or without therapy will have. The ENDOCOVID project aims to investigate whether and how HIV-infection in COVID-19 patients modulates the time course of the disease, alters cardiovascular risk, and changes vascular endothelial function and coagulation parameters/ thrombosis risk.

Methods: In this long-term study, cardiovascular research on PLHIV with or without ART with COVID-19 and HIV-negative with COVID-19 will be carried out via clinical and biochemical measurements for cardiovascular risk factors and biomarkers of cardiovascular disease (CVD). Vascular and endothelial function will be measured by brachial artery flow-mediated dilatation (FMD), carotid intima-media thickness (IMT) assessments, and retinal blood vessel analyses, along with vascular endothelial biomarkers and coagualation markers. The correlation between HIV-infection in COVID-19 PLHIV with or without ART and its role in enhancement of cardiovascular risk and endothelial dysfunction will be assessed. Potential changes in these endpoints by COVID-19 will be followed for 4 weeks across the three groups (PLHIVwith or without ART and HIV negatives).

Impact of project: The ENDOCOVID project aims to evaluate in the long-term the cardiovascular risk and vascular endothelial function in PLHIV thus revealing an important transitional cardiovascular phenotype in COVID-19.

Read the detailed description

Background:

SARS-CoV-2 has affected almost every country worldwide with regard to health system capacities and economic burden, so far. The typical clinical presentations of COVID-19 are fever, sore through, cough, dyspnea, abdominal pain and diarrhea. Approximately 15% of patients with COVID-19 must be hospitalized and 5% are critically ill, and often develop acute respiratory distress syndrome and need to be admitted to intensive care units. Risk of severe disease increases with age, male sex, and with co-morbidities such as chronic lung disease, CVDs, and diabetes. COVID-19 can also affect the nervous systems and cause loss of smell or taste sensation.

Populations in SSA are increasingly facing a double burden of disease involving the interaction between HIV-AIDS and non-communicable diseases such as CVDs. In general, vascular endothelial function can be regarded as a marker of the net harmful effects of cardiovascular risk factors on the vascular wall. HIV- infected patients have premature atherosclerosis and increased risk of ischemic heart disease. The cardiovascular risk represented by HIV-infection is moreover affected by anti-retroviral treatment (ART). ART may, among other effects, prompt dyslipidaemic and metabolic changes in patients over to systemic immune activation, stimulation of endothelial inflammation and atherosclerosis. However, a recent meta-analysis showed that evidence for - and against - a role for ART in the development of CVDs remains unconvincing and that more research is necessary.

With the current COVID-19 pandemic, which has also spread across Africa, another burden is added. However, thus far it is unclear, what effect the additional COVID-19 co-infection in people with HIV (PLHIV) will have as there are no data yet on how HIV/AIDS a prevalent diseases SSA, will affect COVID-19 infection rates or outcomes. Currently, there is no proof for a higher COVID -19 infection rate in PLHIV compared to HIV-negatives. However, there is a possibility that HIV infection may have an influence on the course of infection. PLHIV who are on ART with a normal CD4 T-cell count and suppressed viral load should not be at an increased risk of severe disease. On the other hand, this theoretically positive situation could be counterbalanced by recent evidence that ART could also have effects on COVID-19. Furthermore, HIV-infected patients may additionally suffer from co-morbidities, which could pose a greater risk of COVID-19 infection. Currently, there is no data available about COVID-19 infection in PLHIV in SSA reflecting who in particular is at high risk for infections, complications and fatal outcomes. As COVID-19 associated multisystem inflammation, and the way organ damage caused by COVID-19 occurring in patients with COVID-19 is still incompletely understood, and current treatment options are limited. There is therefore an urgent need to better understand the risk of severe and fatal COVID-19 outcomes, especially in PLHIV (+/- ART).

A severe course of COVID-19 can cause the development of COVID-19-associated coagulopathy, with features of both disseminated intravascular coagulation and thrombotic microangiopathy, resulting in widespread microvascular thrombosis that may involve consumption of coagulation factors and the liver. There seems to be a causal relationship with the inflammatory and reparative processes involving diffuse alveolar damage (DAD), because thrombi are frequently detected in small pulmonary arteries, most presumed secondary to endothelial damage. The damage of endothelium could be due to the direct viral infection of the endothelial cells, which express ACE-2 receptors, or to a host response. Besides, the alveolar fibrin deposition in DAD may affect the local homeostasis between fibrinolysis and coagulation. Alveolar and endothelial damage of smaller vessels may be followed by microvascular pulmonary thrombosis, which could then extend to larger vessels. Additionally, elevated D-dimer has been observed in patients with COVID-19. It is known that inceased D-dimer is associated with acute pulmonary emboli (APE), deep venous thrombosis (DVT), cancer, peripheral vascular disease, inflammatory diseases and pregnancy. It has been found that patients with COVID-19, including those not on respirators but bedconfined, develop DVT and APE much earlier than expected. Even with usage of prophylactic anticoagulation, autopsy has shown that deaths in COVID-19 may be caused by the thrombosis in segmental and subsegmental pulmonary arterial vessels. ENDOCOVID project aims to evaluate the degree to which COVID-19 induced inflammation contributes to endothelial function and coagulation changes and cardiometabolic risk in PLHIV (+/-ART). Endothelial function will be evaluated non-invasively via FMD and blood asymmetric dimethyl arginine (ADMA).

Problem statement HIV infection is a burden for the cardiovascular system but coinfection of HIV and SARS-CoV-2 in SSA population could be a very big load and could lead to higher menace of cardiovascular health. However, the potential of risk in this population, including early vascular and endothelial changes, is yet unclear. Given the ongoing global pandemic, epidemiological studies to address this knowledge gap is necessary. The aim of this study is to evaluate cardiovascular risk in HIV and COVID-19 populations, which also would allow assessment of current - and future - cardiovascular risk, via vascular endothelial function measurements. The ENDOCOVID project has been designed to give an evaluation of cardiovascular risk in PLHIV and COVID-19 living in SAA. ENDOCOVID builds up on the EndoAfrica study, which is currently being carried out in SSA.

Aim and objectives The general aim of the ENDOCOVID project is to identify whether and how HIV-infection with or without ART in COVID-19 patients relates to the time course of the disease, alters cardiovascular risk, and changes vascular endothelial structure and function in adults living in the SSA.

Three groups of participants will take part in this project:

  1. PLHIV without ART but with COVID-19
  2. PLHIV with ART and COVID-19
  3. HIV-negative patients with COVID-19, sex- /age matched

The following objectives will be investigated:

  1. Evaluation of the prevalence of COVID-19 in PLHIV (with or without ART) admitted to clinics in South Africa and Nigeria because of COVID-19.
  2. Assessment of the incidence of acute respiratory distress syndrome, admission to ICU, fatal course of disease (30-days mortality), and thromboembolic events in hospitalized patients included in the study.
  3. Evaluation of the influence of ART on severity of COVID-19 in PLHIV (with or without ART) as well as clinical presentation, changes of endothelial/vascular function and biomarkers.
  4. Evaluation of the effects of COVID-19 on endothelial/vascular function, thrombotic factors, and oro-naso sensory alterations over infection and after recovery.
  5. Correlation of hospitalization and mortality of COVID-19 infected PLHIV(with or without ART) and HIV negatives with co-morbidity incidence;
  6. Assessment of the incidence of obesity and insulin resistance in the 3 groups.
03

Conditions studied

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Participants of the ENDOCOVID study population are patients with COVID-19, who at the same time are infected with HIV (with or without ART), or are HIV negative. Some may be admitted in the ICU. For inclusion into the study, participants must be positive for SARS-CoV-2 RNA and 18 years or older. Participants will be excluded from the study if they are less than 3 months post-partum and those with other co-infections than HIV such as tuberculosis Participants fulfilling the criteria will be invited into the study and asked to provide written informed consent.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • PLHIV without antiretroviral therapy but with COVID-19 infection
  • PLHIV with antiretroviral therapy and COVID-19 infection
  • -negative patients, sex- and age matched, infected with COVID-19;
  • older than 18 years

Exclusion criteria

Exclusion criteria:

  • Those with known co-infections such as and C
  • with a viral load of RNA >1000 copies/ml under ART or with advanced symptoms of AIDS
  • negative for SARS-CoV-2 RNA
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
342 participants (actual)
Target follow-up
4 Weeks
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • COVID-19 positive, HIV-positive with ART

    Patients tested positive for SARS-CoV-2 Patients tested positive for HIV who are on ART

    Biological: COVID-19 · Biological: HIV · Drug: ART

  • COVID-19 positive, HIV-positive without ART

    Patients tested positive for SARS-CoV-2 Patients tested positive for HIV ART naive group

    Biological: COVID-19 · Biological: HIV

  • COVID-19 positive, HIV-negative

    Patients tested positive for SARS-CoV-2 Patients tested positive for HIV ART naive group

    Biological: COVID-19

Interventions

  • BiologicalSARS-COV2Studies of SARS-COV2SARS-COV2 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients diagnosed with a COVID-19 infection

    Also known as: SARS-CoV-2 positive

  • BiologicalHIV

    Patients diagnosed HIV-positive

  • DrugART

    Patients on ART

06

What researchers measure

Primary outcomes

  1. Number of patients developing Acute Respiratory Distress Syndrome

    Comparison of all three groups, recorded for each patient

    Time frame: through study completion, up to 3 months

  2. Number of ICU admissions

    Comparison of all three groups, recorded for each patient

    Time frame: through study completion, up to 3 months

  3. Number of Deaths

    Comparison of all three groups

    Time frame: through study completion, up to 3 months

Secondary outcomes

  1. Cardiometabolic Status: ADMA

    Asymmetric dimethylarginine (ADMA) as marker for endothelial function (from blood sample) measured via commercially available ELISA kits

    Time frame: through study completion, an average of 3 months

  2. Cardiometabolic Status: Cholesterol

    To assess the lipid profile, cholesterol levels will be assessed via blood samples in a routine laboratory

    Time frame: through study completion, an average of 3 months

  3. Cardiometabolic Status: Triglycerides

    To assess the lipid profile, triglyceride concentrations will be assessed via blood samples in a routine laboratory

    Time frame: through study completion, an average of 3 months

  4. Cardiometabolic Status: HDL cholesterol

    To assess the lipid profile, HDL cholesterol concentrations will be assessed via blood samples in a routine laboratory

    Time frame: through study completion, an average of 3 months

  5. Cardiometabolic Status: LDL cholesterol

    To assess the lipid profile, LDL cholesterol concentrations will be assessed via blood samples in a routine laboratory

    Time frame: through study completion, an average of 3 months

  6. Cardiometabolic Status: Glucose

    Assessed via blood samples in a routine laboratory

    Time frame: through study completion, an average of 3 months

  7. Cardiometabolic Status: Glycated Hemoglobin

    HbA1c as marker for diabetes, assessed via blood samples in a routine laboratory

    Time frame: through study completion, an average of 3 months

  8. Cardiometabolic Status: hs-CRP

    high sensitivity CRP as inflammatory marker, assessed via blood samples in a routine laboratory

    Time frame: through study completion, an average of 3 months

  9. Endothelial function and vascular changes: FMD

    Assessed non-invasively using ultrasound in the brachial artery (flow mediated dilatation)

    Time frame: through study completion, an average of 3 months

  10. Endothelial function and vascular changes: PWV

    PWV, a marker of aortic stiffness, is most commonly measured as the time it takes a pulse wave to travel from the carotid to the femoral arteries divided by the distance multiplied by 0.8. PWV can be measured by several devices. The non-invasive Vicorder device has been shown to have good reproducibility - even when the assessor has limited experience in its usage - and the results obtained reflect those obtained via invasive central blood pressure measurements and those of SphygmoCor device.

    Time frame: through study completion, an average of 3 months

  11. Endothelial function and vascular changes: Retinal microvasculature analysis

    A non-mydriatic, hand-held, portable digital retinal camera (Optomed Aurora, Optomed Oy, Oulu, Finland) will be used for collecting retinal images. Dimensions of vessels and microvascular state will be analyzed offline with the semi-automated MONA REVA software (VITO, Belgium).

    Time frame: through study completion, an average of 3 months

  12. Endothelial function and vascular changes: IMT

    Intima media thickness is assessed via ultrasound in the carotid artery

    Time frame: through study completion, an average of 3 months

  13. Coagulatory Parameters: D-dimer

    increased D-Dimer as marker for pulmonary embolism in a routine laboratory

    Time frame: through study completion, an average of 3 months

  14. Coagulatory Parameters: CAT

    Calibrated automated thrombography as thrombosis marker (Thrombinoscope BV)

    Time frame: through study completion, an average of 3 months

  15. Coagulatory Parameters: TF

    Tissue factor (TF) measured via triggered thromboelastometry (TEM) coagulation analyzer (ROTEM05)

    Time frame: through study completion, an average of 3 months

07

Study locations

3 sites
  • University of Ilorin Teaching Hospital
    Ilorin, Kwara State, Nigeria
  • Lagos Stae University Teaching Hospital Ikeja
    Lagos, Nigeria
  • Walter Sisulu University
    Mthatha, South Africa
08

References and documents

Publications

  • Goswami N, Fredriksen PM, Lundin KEA, Agu C, Elias SO, Motaung KS, Brix B, Cvirn G, Sourij H, Stelzl E, Kessler HH, Salon A, Nkeh-Chungag B. COVID-19 and its effects on endothelium in HIV-positive patients in sub-Saharan Africa: Cardiometabolic risk, thrombosis and vascular function (ENDOCOVID STUDY). BMC Infect Dis. 2021 Jul 31;21(1):719. doi: 10.1186/s12879-021-06426-8. PubMed 34332551 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Jun 2024, 40 months.

Of 1,640 non-industry observational studies under COVID-19, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's 40 months is above that.

Counting every sponsor, half of 1,774 studies reached it within 13 months; a quarter within 5 and three quarters within 29.

Completion moved once since we started tracking on Sep 25, 2026: Dec 2025 → Jun 2024, on Oct 8, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2021
First posted
Jan 14, 2021
StartActual
Feb 1, 2021
Primary completionActual
Jun 30, 2024
CompletionActual
Jun 30, 2024was Dec 2025
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Enrolling by invitation→Completed
changed Oct 8, 2026
Study completion
Dec 2025→Jun 30, 2024 (actual)
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Enrolling by invitation→Completed
    Study completion Dec 2025→Jun 30, 2024 (now actual)
    + 3 other changes: index terms, verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04709302
Collaborators
University of Olso, Kristiania University College, Walter Sisulu University, Lagos State University, Management Sciences for Health
Responsible party
Sponsor
First posted
Jan 14, 2021
Start date
Feb 1, 2021
Primary completion
Jun 30, 2024
Completion
Jun 30, 2024
Last update
Oct 8, 2026

Study contacts

Nandu Goswami, Dr PhD
principal investigator · Medical University of Graz

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion